Immunotherapy: is a type of cancer treatment the helps the immune system to fight cancer. The immune system helps your body fight infections and other diseases. It uses substances made by the body or in a laboratory in order to improve or restore the body's immune system function.
Over a year into the COVID-19 pandemic, key vulnerable populations in the United States and across the world lack access to effective vaccines. IDRI has developed technology that addresses s...
With an introduction by Sarah Warren, the Senior Director of Translational Science, this webinar will open by providing a brief technology overview of NanoString Technologies. Dr. Warren wil...
DATE: February 09, 2021 TIME: 08:00am PST Flow cytometry immunophenotyping has become one of the mainstream applications for the diagnosis and classification of several hematologic neoplasms...
Date: February 3, 2021 Time: 8:00am (PST), 11:00am (EST) This introduction webinar will provide you with an overview of the general immuno-oncology (IO) research field...
Date: January 19, 2021 Time: 8:00am (PST), 11:00am (EST) Only a small subset of patients with clear cell Renal Cell Carcinoma (ccRCC) respond to immunotherapy with checkpoint inhibitors. Res...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and has spread globally, causing a pandemic of respiratory illness designated coronavirus disease 20...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
DATE: November 5, 2020 TIME: 9:00am (PDT), 12:00pm (EDT) With accelerating development and approval of cell therapies, biologic drugs, and antiviral treatments comes a need for more robust a...
DATE: Novemb 3, 2020 TIME: 8:00am PST, 11:00am EST Following on from Miltenyi Biotec’s renowned webinar “Improve your CAR T cell research”, this webinar covers our latest p...
DATE: October 20th, 2020 TIME: 08:00am PT, 11:00am ET Tumor-associated macrophages (TAMs) are key cells in the tumor microenvironment (TME) with diverse immune functions that have a major in...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in onc...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Martin highlights various factors impacting molecular analysis from FFPE samples and key challenges and considerations while working with this precious yet challenging sample type. Learning...
Antibodies have become one of the most important tools in life science research, allowing the detection, quantitation, and determination of changes in proteins and other molecules with respe...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Individuals of under-represented minority ancestry are at disproportional risk for higher incidence and mortality rates for particular cancers. The unequal burden of cancer in certain racial...
Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and mor...
Background: Healthcare access (HCA) encompasses five important dimensions: Affordability, Availability, Accessibility, Accommodation and Acceptability. Published studies of cancer typically...
Learning Objectives: 1. To provide an overview of relevant hereditary cancer syndromes 2. To encourage providers to obtain a thorough family history 3. To educate providers about available r...
Over a year into the COVID-19 pandemic, key vulnerable populations in the United States and across the world lack access to effective vaccines. IDRI has developed technology that addresses s...
With an introduction by Sarah Warren, the Senior Director of Translational Science, this webinar will open by providing a brief technology overview of NanoString Technologies. Dr. Warren wil...
DATE: February 09, 2021 TIME: 08:00am PST Flow cytometry immunophenotyping has become one of the mainstream applications for the diagnosis and classification of several hematologic neoplasms...
Date: February 3, 2021 Time: 8:00am (PST), 11:00am (EST) This introduction webinar will provide you with an overview of the general immuno-oncology (IO) research field...
Date: January 19, 2021 Time: 8:00am (PST), 11:00am (EST) Only a small subset of patients with clear cell Renal Cell Carcinoma (ccRCC) respond to immunotherapy with checkpoint inhibitors. Res...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and has spread globally, causing a pandemic of respiratory illness designated coronavirus disease 20...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
DATE: November 5, 2020 TIME: 9:00am (PDT), 12:00pm (EDT) With accelerating development and approval of cell therapies, biologic drugs, and antiviral treatments comes a need for more robust a...
DATE: Novemb 3, 2020 TIME: 8:00am PST, 11:00am EST Following on from Miltenyi Biotec’s renowned webinar “Improve your CAR T cell research”, this webinar covers our latest p...
DATE: October 20th, 2020 TIME: 08:00am PT, 11:00am ET Tumor-associated macrophages (TAMs) are key cells in the tumor microenvironment (TME) with diverse immune functions that have a major in...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in onc...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Martin highlights various factors impacting molecular analysis from FFPE samples and key challenges and considerations while working with this precious yet challenging sample type. Learning...
Antibodies have become one of the most important tools in life science research, allowing the detection, quantitation, and determination of changes in proteins and other molecules with respe...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Individuals of under-represented minority ancestry are at disproportional risk for higher incidence and mortality rates for particular cancers. The unequal burden of cancer in certain racial...
Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and mor...
Background: Healthcare access (HCA) encompasses five important dimensions: Affordability, Availability, Accessibility, Accommodation and Acceptability. Published studies of cancer typically...
Learning Objectives: 1. To provide an overview of relevant hereditary cancer syndromes 2. To encourage providers to obtain a thorough family history 3. To educate providers about available r...